CompletedPhase 2NCT01681940
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
Studying Alpha-mannosidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zymenex A/S
- Principal Investigator
- Allan M Lund, MDCopenhagen University Hospital, Center for Metabolic Diseases, Department for Clinical Genetics
- Intervention
- Lamazym(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 5-21 years · All sexes
- Timeline
- 2012 – 2013
Study locations (4)
- Kinderneurologie Metabole Ziekten, UZ Brussel, Laarbeeklaan 101, Brussels, Belgium
- Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
- Servicio de Pediatría, Hospital Materno Infantil, Reina Sofía, Avda Menéndez Pidal sn, Córdoba, Spain
- Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,, Manchester, United Kingdom
Collaborators
European Commission
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01681940 on ClinicalTrials.govOther trials for Alpha-mannosidosis
Additional recruiting or active studies for the same condition.